Enterprise Value

4.363M

Cash

116.7M

Avg Qtr Burn

-21.03M

Short % of Float

3.46%

Insider Ownership

9.23%

Institutional Own.

43.46%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Azer-cel (PBCAR0191) (azercabtagene zapreleucel) Details
Cancer, B-cell lymphoma, Diffuse large B cell lymphoma

Phase 1/2

Update

ECUR-506 Details
Ornithine transcarbmylase deficiency

Phase 1/2

Initiation

PBCAR19B (CD19 Allogeneic CAR-T) Details
Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma

Phase 1

Update

PBCAR20A (targeting CD20) Details
Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia

Failed

Discontinued

PBCAR269A (BCMA) Details
Cancer, Multiple myeloma

Failed

Discontinued